 Cyclacel Pharmaceuticals, Inc. NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company, a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2019 achievements and outlining the Companys key business objectives for 2020. Cyclacels clinical and business strategy will be highlighted at a presentation during Biotech ShowcaseTM 2020 on Monday, January 13, 2019 at 9:30 a.m. PT in the Yosemite A Suite Ballroom level at the Hilton San Francisco Union Square. During 2019 we have been excited to observe evidence of anticancer activity with CYC065, our CDK29 inhibitor, in patients with both solid and liquid cancers, said Spiro Rombotis, President and Chief Executive Officer. 